atezolizumab,cabozantinib
exelixis,roche
['nsclc', 'atezo', 'cosmic-021', 'sclc']
results from multicohort phase 1b cosmic-021 study: cabo atezo combo showed encouraging clinical activity and manageable toxicity in non-oncogene addicted ansclc pts previously treated with icis #asco22 #earlydrugdevelopment 
Resident in Medical Oncology at Alma Mater University Hospital, Bologna. Passionate about lung cancer, genomics and early drug development.